Aurinia Pharmaceuticals INC Form 4 insider transactions

Chief Medical Officer Greg Keenan reports acquisition and disposal of Aurinia Pharmaceuticals stock and stock options.

Chief Financial Officer Joseph M. Miller reports acquisition and disposal of Aurinia Pharmaceuticals Inc. stock and stock options.

Stephen P. Robertson, EVP and General Counsel of Aurinia Pharmaceuticals, reports transactions involving common stock and derivative securities, including acquisitions, disposals, and option grants.

Chief Operating Officer of Aurinia Pharmaceuticals, Matthew Maxwell Donley, reports acquisition and disposal of company stock and derivative securities.

Director Kevin Tang reports several purchases of Aurinia Pharmaceuticals (AUPH) common shares, significantly increasing his indirect holdings.

Director Kevin Tang of Aurinia Pharmaceuticals has increased his holdings through a series of open market purchases of common shares.

Director Karen L. Smith of Aurinia Pharmaceuticals reported the acquisition of restricted stock units and stock options.

Director Jill Leversage of Aurinia Pharmaceuticals reported the acquisition of restricted stock units and stock options.

Director Craig Johnson of Aurinia Pharmaceuticals acquired 20,631 restricted stock units and 31,688 stock options on November 21, 2024.

Aurinia Pharmaceuticals director Jeffrey Allen Bailey acquired 12,135 common shares and 18,641 stock options on November 21, 2024.

Director David R.W. Jayne acquired 12,135 restricted stock units and 18,641 stock options in Aurinia Pharmaceuticals.

A director at Aurinia Pharmaceuticals sold 4,557 shares to cover tax obligations after the vesting of restricted stock units.

Director Karen L. Smith of Aurinia Pharmaceuticals reported the acquisition of 17,913 shares through vested restricted stock units and the sale of 5,241 shares to cover tax obligations.

R. Hector MacKay-Dunn, a former director of Aurinia Pharmaceuticals Inc., filed a Form 4 indicating a change in beneficial ownership of the company's securities.

Scott Michael Habig, Chief Commercial Officer of Aurinia Pharmaceuticals, sold 18,249 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Director Brinda Balakrishnan sold 520 shares of Aurinia Pharmaceuticals to cover tax withholding obligations related to vesting of Restricted Stock Units.

Director Daniel Billen sold 5,252 shares of Aurinia Pharmaceuticals to cover tax obligations related to vesting restricted stock units.

David R.W. Jayne, a director of Aurinia Pharmaceuticals, sold 4,946 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Jill Leversage, a director at Aurinia Pharmaceuticals, sold 5,610 shares of common stock on May 21, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Director R. Hector MacKay-Dunn sold 5,630 shares of Aurinia Pharmaceuticals to cover tax withholding obligations related to vesting Restricted Stock Units.

Aurinia Pharmaceuticals' CEO, Peter Greenleaf, sold 126,981 shares of common stock on March 6, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Joseph M. Miller, CFO of Aurinia Pharmaceuticals, sold 34,811 shares of common stock on March 6, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Matthew Maxwell Donley, EVP of Operations & Strategy at Aurinia Pharmaceuticals, sold 40,665 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Chief Commercial Officer Scott Michael Habig sold 17,777 shares of Aurinia Pharmaceuticals to cover tax withholding obligations related to vesting Restricted Stock Units.

Stephen P. Robertson, EVP and General Counsel of Aurinia Pharmaceuticals, sold 57,745 shares of common stock on March 6, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Volker Knappertz, EVP of Research and Development at Aurinia Pharmaceuticals, sold 4,930 shares of common stock on February 27, 2024.